Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00932737 · ClinicalTrials.gov registry record · Phase 2

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

A Phase 2 study of Abdominal Pain, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 2
Development phase
197
Enrollment target
19
Study locations

NCT00932737: Completed Phase 2 study of Abdominal Pain, sponsored by Boehringer Ingelheim.

NCT00932737 is a Phase 2 study of Abdominal Pain that has completed, run by Boehringer Ingelheim. The registered enrollment target is 197 participants, above the 140-participant average among 19 other Abdominal Pain trials with a reported enrollment target (41% higher). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00932737, a Phase 2 study of Abdominal Pain, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 2
Development phase
197 participants
Enrollment target
19
Study locations

Study Summary

The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated with cramping (APC) in the treatment of two episodes.

Primary Outcome

The intensity of Abdominal pain associated with cramping was rated on an 11-point numeric pain rating scale (NPRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine).

Conditions Studied

Abdominal Pain

Interventions

  • DRUG Placebo
  • DRUG HBB 20 mg

Study Locations (19)

Florida

  • 202.839.01003 Boehringer Ingelheim Investigational Site - Hollywood
  • 202.839.01001 Boehringer Ingelheim Investigational Site - Jupiter
  • 202.839.01002 Boehringer Ingelheim Investigational Site - Jupiter

Oklahoma

  • 202.839.01021 Boehringer Ingelheim Investigational Site - Norman
  • 202.839.01010 Boehringer Ingelheim Investigational Site - Oklahoma City

Texas

  • 202.839.01006 Boehringer Ingelheim Investigational Site - San Antonio
  • 202.839.01012 Boehringer Ingelheim Investigational Site - San Antonio

California

  • 202.839.01014 Boehringer Ingelheim Investigational Site - Westlake Village

Illinois

  • 202.839.01017 Boehringer Ingelheim Investigational Site - Rockford

Indiana

  • 202.839.01005 Boehringer Ingelheim Investigational Site - Indianapolis

Maryland

  • 202.839.01019 Boehringer Ingelheim Investigational Site - Chevy Chase

Massachusetts

  • 202.839.01009 Boehringer Ingelheim Investigational Site - Boston

Trial Details

FieldValue
Enrollment Target 197 participants
Start Date 2009-06-09
Est. Completion 2010-02-08
Phase Phase 2
Boehringer Ingelheim

515 total trials

What the finished NCT00932737 record still lists

NCT00932737 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, above the 140-participant average among 19 other Abdominal Pain trials with a reported enrollment target (41% higher).

The record links to 1 condition, with Abdominal Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00932737 lists 19 locations in 15 states (Florida, Oklahoma, Texas).

Frequently Asked Questions

What is clinical trial NCT00932737 about?

NCT00932737 is a clinical study titled "(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis". The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated with cramping (APC) in the treatment of two episodes.

What is the current status of trial NCT00932737?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2009-06-09. Estimated completion is 2010-02-08.

What conditions does trial NCT00932737 study?

This clinical trial studies the following conditions: Abdominal Pain.

What interventions are being tested in trial NCT00932737?

The interventions under investigation include: Placebo (DRUG), HBB 20 mg (DRUG).

Who is sponsoring clinical trial NCT00932737?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00932737 being conducted?

This trial has 19 study locations across California, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Abdominal Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00932737's enrollment target sits among peer trials

197 6th of 19 higher than 14 of 19 other Abdominal Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Abdominal Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04219254 · 197 participants · Phase 1

    A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

  • NCT06173778 · 197 participants · Phase 2

    Semaglutide for Post-Smoking Cessation Weight Management

  • NCT05203328 · 198 participants · NA

    Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy

  • NCT05426967 · 198 participants · NA

    rTMS for Military TBI-related Depression

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00932737, the US trial registry maintained by the National Library of Medicine. NCT00932737 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.